Lobular Research

Advocate for Invasive Lobular Carcinoma (ILC) Breast Cancer patients. Rationally exuberant for Immuno-Oncology.

[Lobular Research @LobularResearch]

First ever International #Lobular #breast #cancer symposium. Pittsburgh, PA, USA. Sept 2016. https://t.co/dpYAeaoXJd

[Lobular Research @LobularResearch]

@BreastDense @PWBDerksen @cancercenterumc @BeingDense- Focused on Lobular & TNBC, the RATHER consortium was a large multidisciplinary collaborative project funded by the EU & led by University College Dublin.
https://t.co/E4u1haZFmo
I’d turn over every stone to find out who was involved w/ ILC advocacy w/ this project.

[Lobular Research @LobularResearch]

@EricTopol @CellStemCell @CellPressNews @StanfordMed Off-the-shelf, induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell cancer immunotherapy is now available in clinical trials. https://t.co/PTWYoJHJEG

[Lobular Research @LobularResearch]

Great news!

[Dr. Steffi Oesterreich @oesterreichs]

Save the date May 14-16, 2020, for 2nd International ILC Symposium In #Pittsburgh @LobularBCA #lobmob #Lobular #bcsm @LPseattle @hiplinemedia @Otto_DFCI @PWBDerksen @c_sotiriou @UPMCHillmanCC @mjsikora @BCRFcure @SusanGKomen

[Lobular Research @LobularResearch]

@oesterreichs @LobularBCA @LPseattle @hiplinemedia @Otto_DFCI @PWBDerksen @c_sotiriou @UPMCHillmanCC @mjsikora @BCRFcure @SusanGKomen This is GREAT news! Thank you!

[Lobular Research @LobularResearch]

#Lobular related abstracts at #AACR19
TMB, PD-L1 status & Checkpoint Inhibitors
https://t.co/VRWaXRS3cZ

[18F]FDG PET/CT imaging
https://t.co/LDsW55NoaX

NCI-MATCH EAY131 arm B: Phase II study of afatinib in patients with HER2 (ERBB2) activating mutations
https://t.co/FoSs9HWbc8

[Lobular Research @LobularResearch]

Great news for the #Lobular breast cancer community.

New Lobular Breast Cancer Registry Will Shed Light on Rare Disease https://t.co/DH5ZtiQXsH via @CleClinicMD

[Lobular Research @LobularResearch]

@CBrisken @ICPInews Were these immunodeficient mice? just wondering if this mouse model would be useful for investigating cancer immunotherapies?

[Lobular Research @LobularResearch]

Susan Potter (breast cancer survivor) gave her body to science. Her cadaver became immortal. https://t.co/vrTDMnQTU5 via @NatGeo

[Lobular Research @LobularResearch]

Small historical studies reveal ~50% of Lobular breast cancers over-express ROR1 (not to be confused with ROS1). If validated, could Anti-ROR1 CAR-T immunotherapy be a future option for mILC?

CAR T-Cell Therapy Shows Early Potential in TNBC https://t.co/8uXjqhpNpw via @onclive

[Christine Simmons @DrCESimmons]

#SABCS18 genomic and immune characterization of lobular breast cancer presented by Dr. Desmedt underscores the fact that lobular breast cancer is different from ductal both clinically and in the mutations that occur. Need to think about optimal treatment strategies! #bcsm

[George W Sledge MD @GeorgeSledge51]

#SABCS18 Desmedt on lobular cancer progression and endocrine resistance. Uses 73 matched primary and mets (great). Increased ESR1, IGF1R, HER2 mutations. Increased AKT1. Each of these has potential to alter therapy.

[Julie Gralow @jrgralow]

Impassion 130: PD-L1 expression on TILs best predictor of benefit from atezo (immune checkpoint inhibitor). Even expression at 1% level showed benefit. All metastatic TNBC should be tested for PD-L1 on TILs. #SABCS18 Atezo likely to be FDA approved in this setting in near future

[Patrick WB Derksen @PWBDerksen]

Bringing together Clinical and Biomedical Scientists @cancercenterumc for the 1st European #ILC consortium meeting. Inspiring interactive sessions building towards an improved diagnosis and tailored treatment of #lobular #breastcancer! #ILBC #DerksenLab #UMCUtrecht

[Lobular Research @LobularResearch]

More pre-clinical evidence that suggests synergy between CDK4/6 inhibitors and Checkpoint Blockade to overcome resistance. Perhaps endocrine-sensitive tumors like #Lobular could benefit. Clinical trials needed.

[Broad Institute @broadinstitute]

In @CellCellPress: A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade https://t.co/2ggVN8LQgq

[Lobular Research @LobularResearch]

@EV11PDX Main center has enrolled ~8 patients in 7 months. Other sites are just opening up.
Biopsy is required, so those that have been enrolled have measurable disease, but it's not clear how many have been denied due to unmeasurable disease.

[Lobular Research @LobularResearch]

Worlds first ILC / #Lobular clinical trial using #Immunotherapy [Atezolizumab] launching in Netherlands. Summer 2017
https://t.co/63yreO6jq1

[Lobular Research @LobularResearch]

Wow! Didn’t realize Dr. Leisha Emens was at UPMC. As a thought leader in immunotherapy for breast cancer, this is a big win for Pitt and perhaps a potential windfall for the #Lobular community.

[Adrian Lee @Adrianvlee]

Anti-PD-L1 activity in TNBC. Durable clinical response when given in earlier lines of therapy and when PD-L1 high in immune cells. Proud to have lead author Leisha Emens now as a colleague here in Pittsburgh @UPMCnews @PittTweet @Magee_Womens #bcsm https://t.co/4s5Sq0NhAC

[Lobular Research @LobularResearch]

Intra-lesion genetic heterogeneity in LCIS should be considered in studies aiming to develop biomarkers of progression from LCIS to invasive disease.

[David B. Solit, MD @DSolit]

Great work published yesterday in Clinical Cancer Research by my colleagues Jorge Reis-Filho, Tari King and others on the clonal relatedness of lobular carcinoma in situ and subsequent invasive breast cancers.
https://t.co/5GHhkzYOqz
#breastcancer #LCIS @AACR @sloan_kettering

[Lobular Research @LobularResearch]

Tumor-suppressor genes are often inactivated through changes in mRNA processing that enable expression of truncated proteins. This mechanism of inactivation does not require DNA mutations in the affected genes. https://t.co/VqOFeYg90Z

[Elisabeth Rosenthal @RosenthalHealth]

Today, hospital said it was reducing $108,000 out-of-pocket bill to $782?! @khnews' @chadterhune @npr. Having a journalist's expose settle a bill is not triumph, it's a symptom of a very broken system, as in my book #AnAmericanSickness https://t.co/xKY2MXYYJi